Nanobiotix reported 50,968,893 shares outstanding as of October 31, 2026, alongside 54,726,179 theoretical voting rights and 54,704,061 exercisable voting rights.
NBTX · Nanobiotix S.A.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 44%
- Last earnings
- Apr 1, 2026
- Price history
- Dec 2020 to Nov 2026
Up next
Latest documents
NANOBIOTIX announced management appearances at the Jefferies Global Healthcare Conference on Monday, November 16, 2026, and the UBS Global Biopharma Conference on Tuesday, November 17, 2026, in London.
Nanobiotix reported final Phase 1 data for JNJ-1900 (NBTXR3) with immune checkpoint inhibitors in anti-PD-1-resistant primary cutaneous melanoma. The overall response rate was 41.7% (10/24), including 4 complete responses, with median overall survival of 17.8 months.
Nanobiotix reported that as of September 30, 2026 it had 50,967,610 shares outstanding, with 54,729,543 theoretical voting rights and 54,707,425 exercisable voting rights.
Nanobiotix S.A. appointed Arnd Christ chief financial officer and executive board member effective October 1, 2026; Bart Van Rhijn will step down as chief financial & business officer and board member after five years.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NBTX
this stock
Nanobiotix S.A.
|
$1.35B | +14.6% | — | — | 0.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 34
Nanobiotix reported 50,968,893 shares outstanding as of October 31, 2026, alongside 54,726,179 theoretical voting rights and 54,704,061 exercisable voting rights.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NBTX | -13.6% | -9.7% | -27.9% | -15.5% | +14.6% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -5.0% | -0.5% | -18.7% | -6.8% | +13.5% |